Why the study?
Does the 19 mm Carpentier-Edwards pericardial bioprosthesis provide reliable long-term clinical and structural outcomes in patients with small aortic annuli?
Does the 19 mm Carpentier-Edwards pericardial bioprosthesis provide reliable long-term clinical and structural outcomes in patients with small aortic annuli?
The 19 mm Carpentier-Edwards pericardial bioprosthesis demonstrates low rates of structural deterioration and valve-related events at 10 years, making it a reliable option for patients with small aortic annuli.
Answers are grounded in this paper and cite their sources.
Supports durability of 19 mm pericardial bioprostheses in small annuli; leaves open randomized comparisons.
OBJECTIVE: The first generation of pericardial valves was withdrawn from the market because of too high a rate of premature failure. With an original design, the Carpentier-Edwards pericardial valve promised improved results, especially in small sizes. METHODS: Ninety patients who underwent an isolated aortic valve replacement with a 19 mm Carpentier-Edwards pericardial bioprosthesis in our institution between July 1984 and December 1993 were followed up. The mean age was 72.2 +/- 10.1 years. Fifty percent of the patients were in NYHA clinical status III or IV. The operative mortality rate was 3.7% (3/90). All patients were followed up for an average of 4.45 years after their operation and the total follow-up was 398 patient-years. RESULTS: At this time of the study, over 80% of the patients are in NYHA class I or II. There were nine late deaths. After 10 years the actuarial survival rate was 80 +/- 12%. Three patients died of valve-related causes (1 endocarditis, 1 structural failure and 1 sudden death). The actuarial rate of freedom from valve-related death was 93 +/- 6% at 10 years. Valve-related complications included two thromboembolic episodes (0.5% patient-year), one endocarditis (0.3% patient-year), one reoperation (0.3% patient-year) and one structural valve failure with calcification and stenosis (0.3% patient-year). After 10 years, freedom from reoperation was 99 +/- 1%, from valve failure 98 +/- 2%, from thromboembolic episodes 95 +/- 4% and from endocarditis 98 +/- 2%. The mean gradient was 18.8 mmHg and mean effective orifice area 1.1 cm2. CONCLUSIONS: With a low rate of valve-related events at 10 years and a low rate of structural deterioration with no leaflet tear, this prosthesis is a reliable alternative for small aortic annuli.
No takes yet. Share an insight, caveat, or question.
Aupart et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: